Analysts See $-0.06 EPS for CytoDyn Inc. (CYDY) on July, 19

June 29, 2018 - By Don Salinas

CytoDyn Inc. (OTCMKTS:CYDY) Corporate Logo

CytoDyn Inc. (OTCMKTS:CYDY)’s earnings report is awaited by WallStreet on July, 19, RTT reports. CYDY touched $0.46 during the last trading session after $0.01 change.Currently CytoDyn Inc. is after 0.00% change in last June 29, 2017. CYDY has also 87,945 shares volume. CYDY underperformed by 12.57% the S&P 500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.The firm is valued at $100.60 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.Currently it has negative earnings.

CytoDyn Inc. (OTCMKTS:CYDY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: